MARKET

BMEA

BMEA

Biomea Fusion, Inc.
NASDAQ
2.120
+0.170
+8.72%
After Hours: 2.120 0 0.00% 19:37 04/04 EDT
OPEN
1.890
PREV CLOSE
1.950
HIGH
2.130
LOW
1.860
VOLUME
736.80K
TURNOVER
--
52 WEEK HIGH
16.29
52 WEEK LOW
1.860
MARKET CAP
79.65M
P/E (TTM)
-0.5530
1D
5D
1M
3M
1Y
5Y
1D
IVEY PMI Reading Due Next Week in Canada
Barchart · 2d ago
Biomea Fusion Price Target Cut to $3.00/Share From $11.00 by Barclays
Dow Jones · 4d ago
Biomea Fusion Is Maintained at Equal-Weight by Barclays
Dow Jones · 4d ago
Barclays Maintains Equal-Weight on Biomea Fusion, Lowers Price Target to $3
Benzinga · 4d ago
After Plunging -27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Biomea Fusion (BMEA)
NASDAQ · 4d ago
BIOMEA FUSION INC. <BMEA.O>: BARCLAYS CUTS TARGET PRICE TO $3 FROM $11
Reuters · 4d ago
Biomea Fusion price target lowered to $3 from $11 at Barclays
TipRanks · 4d ago
Barclays Sticks to Their Hold Rating for Biomea Fusion (BMEA)
TipRanks · 4d ago
More
About BMEA
More
Biomea Fusion, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of oral covalent small molecules to treat patients with metabolic diseases and genetically defined cancers. A covalent small molecule is a synthetic compound that forms a permanent bond to its target protein. The Company is utilizing its proprietary FUSION System to discover, design and develop a pipeline of covalent-binding small molecule medicines designed to maximize clinical benefit for patients. Its lead product candidate, BMF-219, is designed to be an oral, potent, and selective covalent inhibitor of menin, built from its FUSION System. It is developing BMF-219 for the treatment of menin regulated or dependent diseases, such as type 1 and type 2 diabetes as well as subtypes of liquid and solid tumors. Its second development candidate, BMF-500, a covalent inhibitor of activating mutations of the FMS-like tyrosine kinase 3 (FLT3).
Recently
Symbol
Price
%Change

Webull offers Biomea Fusion Inc stock information, including NASDAQ: BMEA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BMEA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BMEA stock methods without spending real money on the virtual paper trading platform.